VERSION 1 -AUTHOR RESPONSE

Reviewer 1
The authors are addressing an interesting and novel topic especially when consider the lack of randomized, placebo controlled clinical trials on polyphenols sources in general, and on algal polyphenols specifically. I think this Manuscript is acceptable for publication, after update on some concerns, such as those listed below.
Although the English is quite good and acceptable for the publication I would suggest to check it once again, especially the use of tenses.
Title: add "double blind" Thank you for this comment. Title now reads, "A study protocol for a double blind randomised controlled trial investigating the impact of 12 weeks' supplementation with a polyphenol-rich brown seaweed extract on cholesterol levels in adults with hypercholesterolaemia" Participants: Considering the number of participants, the age span is quite wide. Do you have any justification on this? Our justification for the wide age range is that we intended to increase the generalisability of the results by including anyone from 18 to 65 years. In addition, our primary inclusion criteria is related to elevated LDL cholesterol levels, which are beginning to appear in younger populations, no longer just middle-aged and older adults. Furthermore, this age range is consistent with previous similar studies (Int. J. Pharm. 11(7):798-805; Phytother. Res. 26(3):363-368).
More importantly, the level of LDL is set to be quite low, since this is a primary outcome. I would not expect a decrease in person having LDL level less than 3 mmol/L also I dont see physiological relevance in decreasing a LDL cholesterol which is already in good range. Thank you for your comment. We have based our lower cut off of 2.0 mmol/L for LDL cholesterol on The National Vascular Disease Prevention Alliance, Guidelines for the management of absolute cardiovascular disease risk (2012), which recommends an LDL level of <2.0 mmol/L as a target for primary prevention to reduce absolute cardiovascular disease risk. Given that our intervention is targeted towards an 'at-risk', but not diseased or medicated population, and that the purpose of the intervention is primary prevention, participants were included if their LDL cholesterol level was above the aforementioned target of 2.0 mmol/L. We have added this reference into the manuscript: "The National Vascular Disease Prevention Alliance recommends an LDL level of <2.0 mmol/L as a target for primary prevention, to reduce absolute cardiovascular disease risk." (page 11).
Exclusion criteria: The authors mention the use of certain medications. Does this imply use of therapy for glucose control, since this is one of the outcomes? Please make it more clear Thank you, we have added clarification here that medications for blood glucose control would also exclude participants. This section now reads "…are taking medication for cholesterol, blood glucose or blood pressure control…" (page 11) Study intervention: Why particularly this amount of polyphenols has been chosen? Any explanations, how does this amount relate to average and recommended daily intake of polyphenols... There is no current recommended daily intake for polyphenols. Based on our own research, the average daily polyphenol intake of a sample of Australian adults is 944 mg per day, with coffee as the largest source, but varies widely (SD 539). However, the polyphenols in seaweed are different to those in coffee and other plant-based foods, so a direct comparison to total polyphenol intake is not appropriate. This dose or marine polyphenols is also similar to that used in another 12 week intervention trial (690 mg/day: Food Funct. 6:853-858) which showed efficacy for lowering blood glucose. In a previous study, we tested two doses of polyphenols, 150 mg (based on a dose that showed efficacy for cholesterol lowering: Phytother. Res. 26(3):363-368) and 600 mg (based on the aforementioned 690 mg dose). Neither of these doses were reported to cause intolerance symptoms, so for the present study we have given higher of the two doses, to maximise the potential for a cholesterol lowering effect.
Also, the dose of fucoidan is quite high, twice as much as the dose of polyphenols. Since authors are claiming polyphenols as active ingredients, this issue should be more elaborated, especially when consider that fucoidan has also potential to act on lipids. Authors should explain why particularly polyphenols would be responsible for health effects, and not both polyphenols and fucoidan... Although I suggested a minor revision, the two concerns should be carefully addressed. These are the inclusion criteria for LDL cholesterol level and the high dose of fucoidan in the extract. In accordance, the Discussion section should be extended. Thank you for highlighting this. We have updated wording throughout the manuscript to reflect that the study is investigating the (polyphenol-rich) brown seaweed extract as a whole, as opposed to the polyphenols individually. We have also included information relating to fucoidan and its potential lipid lowering effects in the introduction: "They contain a number of bioactive compounds with potential to improve health, including polysaccharides, such as fucoidan ((1,2)--L-fucose-4-sulphate with branching or sulphate ester group on C3), and phytochemicals, such as polyphenols." (page 5) "Similarly, treatment with fucoidan-rich brown seaweed extracts have resulted in reductions in serum TG, total and LDL cholesterol levels and increases in HDL cholesterol levels in hyperlipidaemic rats (28 days treatment) and hyperlipidaemic mice (acute 24 hour challenge), through modulation of gene expression and enzyme activity." (page 6) "In a third RCT, 25 overweight or obese volunteers in Mexico consumed 500 mg of a fucoidan-rich brown seaweed extract (containing 25 mg polyphenols), daily. No differences between active and placebo treatments were reported for total cholesterol, TG, or HDL cholesterol levels following 3 months of treatment. However a reduction in LDL cholesterol levels was observed in the treatment group compared with no change in the placebo group." (page 6) And included a paragraph about this in the limitations section of the discussion: "Another limitation of this study is the, potentially confounding, presence of fucoidan in the extract. [5] There is evidence from animal models that fucoidan itself lowers TG, total and LDL cholesterol levels and increases HDL cholesterol. [16, 17] However, the only RCT to investigate this effect in humans used a fucoidan-rich brown seaweed extract that also contained polyphenols.
[20] Therefore, it is unclear whether the fucoidan or polyphenols were responsible for the observed reduction in LDL cholesterol following intervention. [20] Similarly in the observed outcomes from this trial, the role of the fucoidan and polyphenols may be difficult to differentiate. Given there is in vitro and animal model evidence that both brown seaweed polyphenols and fucoidan lower cholesterol levels, [9] [10] [11] [15] [16] [17] the efficacy of the extract as a whole may be more important than determining the effect of its individual components." (page 25) Concerning the inclusion criteria for LDL cholesterol, as well as the aforementioned changes in the methods section, we have also added a paragraph about this into the limitations section of the discussion: "In order to be included in this study, participants must have a fasting LDL cholesterol level greater than 2.0 mmol/L. While this is based on recommendations for primary prevention of CVD from The National Vascular Disease Prevention Alliance, [48] we acknowledge that this cut off (2.0 mmol/L) is classified within the healthy range by other organisations, [66] and therefore the magnitude of change seen following intervention may be less than if the cut off were higher." (page 25) Reviewer 2 The research area is of growing interest both within the general public, industry, and research community. The authors should be commended for their design of Una robust and novel study which will be a significant contribution to the currently limited evidence base. The exploration analysis of cognition is particularly novel. I have the following comments:
1. Although some previous studies have looked at a different type of seaweed, is there any data on the similarity/differences in polyphenol content between to the two varieties? Thank you for this comment; we assume you are referring to the seaweed Ecklonia cava. Previous 12-week human trials have used polyphenols from the seaweed Ecklonia cava. These studies have used extracts of Ecklonia cava, with varying polyphenol contents: -Ecklonia cava extract that contained 8.2% dieckol (J. Med. Food 12 (2) In our own analysis, we determined the total soluble polyphenol content of the present extract to be 36.9% dry weight PGE. When comparing the fresh seaweed varieties polyphenol content is likely to vary due to location, environmental exposures etc. Also, different extracts will vary in polyphenol content depending on extraction procedure and other factors. These factors make it difficult to compare the polyphenol content of two seaweed varieties; it may, therefore, be more important to focus on the polyphenol content in the extracts used.
2. Could you include the population within the secondary aim Thank you, yes the secondary aim now reads "Secondary aims are to investigate the impact of 12 weeks supplementation on fasting total cholesterol, HDL cholesterol, triglyceride, glucose and insulin levels, as well as inflammatory markers and cognitive function in hypercholesterolaemic adults" (page 10) 3. Could you state the effect size/LDL reduction that the power calculation was based on? Yes, this section has been updated to read "Power analyses were performed to identify the required sample size to detect a change in fasting LDL cholesterol level following intervention, at a power of 80%. Using G*Power 3.1.9.2,47 the sample size was calculated based on data from Shin et al48, a similar 12 week algal polyphenol intervention study that observed a reduction in LDL cholesterol levels of 0.5 mmol/L (14%) following intervention. A total sample of 52 individuals, or 26 per treatment group, is required to detect a change of this size in LDL cholesterol level. To account for a dropout rate of approximately 10%, we plan to recruit 58 participants." (page 13) 4. In preintervention, there needs a comma after "baseline testing visit" Thank you this now reads, "Prior to the baseline testing visit, participants will be asked to complete a three-day food diary to assess their baseline dietary habits." (page 13) 5. There is some repetition regarding the FFQ within the preintervention section and the outcome section We agree and have removed detail on the FFQ from the pre-intervention section. This section now reads "Prior to the baseline testing visit participants will be asked to complete a three-day food diary to assess their baseline dietary habits. A food frequency questionnaire (FFQ) [50] will be used to estimate participants' baseline total polyphenol intake. The International Physical Activity Questionnaire (IPAQ) short version will be used to assess baseline physical activity levels.
[51]" (page 13). The detail remains in the outcome section.
6. Regarding outcomes for the polyphenol FFQ, could you state whether you are aiming to investigate total polyphenol intake or subclasses too. Thank you for this suggestion, we are investigating total polyphenol intake. This has now been clarified, please see previous response.
7. In your statistics plan, you have stated how you will handle primary outcomes and the effect of secondary measures on these outcomes. If you are planning any exploratory or secondary analyses, could you also include these here too? Thanks you for your suggestion, but we are not planning any exploratory analyses.
8. "…the secondary outcome of differences…" should be "outcome *for* differences" Thank you, we have changed this sentence to "A mixed between-within subjects analysis of variance (ANOVA) will be used to assess the differences between the groups across the three time points (baseline, week 6 and week 12)" (page 21). We have removed the wording 'secondary outcome', as this confused the meaning of the sentence. The ANOVA will be used to assess all biochemical outcomes across the three time points.
9. Furthermore, can you clarify which analysis you aim to use to determine the effect of secondary measures (e.g. polyphenol intake) on primary outcomes? Potential influencing variables, such as age, sex and polyphenol intake, will be entered into the ANOVA as covariates to assess their influence over the effect of treatment on the biochemical outcomes. Please see the following sentence in the paper "ANOVAs for the biochemical measures will be repeated including the variables of age, gender, change in weight status and usual polyphenol intake added as covariates." (page 21).
10. Are you assessing blinding efficacy? It would be good to include a question during the final interview to determine if participants knew which arm they were assigned to. Particularly useful for self-reported measures such as mood. Thank you for this suggestion, however, given that the primary outcomes of this study are objective biochemical measures, we are not assessing blinding efficacy. We will consider including this in future studies, but as the present study is currently underway, we are unable to assess this.
11. "Only participants who complete the full study protocol will be included in the analysis." This appears to be a per-protocol analysis. Intention to treat is generally preferred analysis to reduce bias as per Cochrane and other guidelines. You may wish to revise this part of the analysis to include an intention-to-treat analysis for primary analysis as well as a per-protocol analysis. 12. Could you also include some information about how missing data will be handled (e.g imputation?) Thank you for this suggestion. As requested, we have decided to include a modified intention to treat analysis, as well as the per-protocol analysis. The manuscript now reads, "A per-protocol analysis will be carried out, in which only participants who complete the full study protocol will be included. Any participants with less than 80% compliance will be considered as not completing. A modified intention to treat (ITT) analysis will also be carried out, in which all randomised participants will be analysed in their randomisation group, with the last observed value carried forward for missing data. The modification to the ITT protocol will be the exclusion of participants who were randomised but did not complete baseline measures." (page 21).
13. "Participants who meet the inclusion criteria will be invite to a screening session where they will have a chance to ask any questions and have the study explained to them verbally." Revise "invite" to "invited" Thank you, this change has been made, "Participants who meet the inclusion criteria will be invited to a screening session where they will have a chance to ask any questions and have the study explained to them verbally." (page 22).
14. Regarding data access, do you have any plans to make deidentified datasets available online to other researchers (e.g. shared/open access datasets)? Again thank you for this suggestion, however ethical approval for making the data publically availably was not requested and participants have not been asked to consent to their data becoming publically available. Following completion of the study we may investigate other ways of sharing the data.
15. The discussion section could benefit from summarising the strengths and novel features of your study design and how this strengthens the existing literature Thank you for this suggestion. We have added a strengths section to the discussion to summarise this information. Please see below: "There are a number of novel features in this study design. This trial will be the first to examine the effects of supplementation with a polyphenol-rich Fucus vesiculosus extract in an Australian population for all of the aforementioned outcomes. It will also be the first to investigate the effects of a polyphenol-rich brown seaweed extract on inflammatory markers in humans, though not necessarily powered for this outcome. There are also a number of features of this study designed to add to the existing literature. There have been four previous 12-week RCTs that have investigated the effects of polyphenol-rich brown seaweed extracts on fasting cholesterol and/or blood sugar levels. [15] [16] [17] 29] This study has been designed as a double blind, placebo controlled randomised parallel trial, the gold standard for determining the effect of an intervention,[61] with a similar duration and population to previous studies, in order to add to this growing evidence base." (page 24) 16. Could the authors comment on if this trial design/implementation is in adherence to the Good Clinical Practice guidelines? Thank you, and yes, this trial is in adherence with the Good Clinical Practice guidelines. The Principle Investigator holds a Good Clinical Practice certification, and the Monash University Human Research Ethics Committee has approved all procedures.
FORMATTING AMENDMENTS (if any)
Required amendments will be listed here; please include these changes in your revised version: -Kindly re-upload FIGURES with at least 300 dpi resolution. 300 dpi figures will be uploaded with revision. There was no involvement of patients or the public in the development of the research question, outcome measures or study design. Study participants will not be directly involved in recruitment, however, snowballing through word of mouth is a part of the recruitment strategy. Furthermore, given that the intervention will involve taking a daily supplement, with no other lifestyle change, participants will not be asked to assess the burden of the intervention. Findings from this research will be disseminated to study participants as detailed below." (page 21)
VERSION 2 -REVIEW
REVIEWER
Nevena Vidovic Institute for Medical Research, University of Belgrade, Serbia REVIEW RETURNED 05-Jul-2018
GENERAL COMMENTS
Although the authors are addressing an important topic, in my opinion, this manuscript is not acceptable for publication. In my opinion, the investigation on the effects on LDL cholesterol levels has not importance in subjects who are only a modest risk (have LDL > 2 mmol/L). Although the authors referred to National guide, other regulatory bodies suggest much higher values as risk factors. Also, the authors based their aim on previous studies that have investigated the impact of brown seed extracts. But this studies included participants with higher baseline LDL levels: Reference 15: low dose extract: baseline LDL 3,76 ± 1,04 decreased by 10%, high dose extract LDL baseline 3,7 ± 0,78 decreased by 14,25%; Reference 16: LDL > 2,849 and LDL decreased by 11 %; Reference 17: LDL 3,1 ±0,5 and LDL decreased by 13%: The authors classified potential participants as subject with hypercholesterolemia, although they would be, with suggested BMI, overweight and obese. In section Sample size calculation, the authors referred to the decrease of 0,5 mmol/L which was seen in one study. Still, in that study, the decrease of 0,5 accounted for 14% (implying that the starting values of LDL were higher than 3,5 mmol/L). On the other side, authors suggested values of LDL higher than 2 mmol/L meaning that decrease of 0,5 would account for more than 20 % (up to 25 %), which according to all studies the authors have cited (mentioned above) is not likely to occur (considering those studies included participants with higher baseline LDL values and recorded lower degree of reduction). Further on, the authors classify the extract as polyphenol-rich although the extract besides that contains fucoidan in high amounts...
REVIEWER
Wolfgang Marx
Food&Mood Centre, Deakin University, Australia REVIEW RETURNED 06-Jul-2018
GENERAL COMMENTS
The authors have addressed all queries. I have no further comments.
VERSION 2 -AUTHOR RESPONSE
Reviewer 1 1. Although the authors are addressing an important topic, in my opinion, this manuscript is not acceptable for publication. In my opinion, the investigation on the effects on LDL cholesterol levels has not importance in subjects who are only a modest risk (have LDL > 2 mmol/L). Although the authors referred to National guide, other regulatory bodies suggest much higher values as risk factors. The reviewer may have misunderstood the use of the 2.0 mmol/L cut-off. That is, we have included the criterion that participants have a fasting LDL cholesterol level of above 2.0 mmol/L, by definition the sample is likely to have a mean LDL level in the range of the studies cited by the reviewer. This has now been clarified in the manuscript. Furthermore, we have selected as the basis for the cholesterol cut-off from nationally relevant guidelines for the population being investigated i.e. Australian. Whilst the authors respect the opinion of the reviewer, this does need to be based on scientific evidence. We have used the scientific evidence available to us to guide our decision to adopt National Clinical Guidelines for our inclusion criteria. The aim of introducing functional ingredients into a population is preventative not curative and, as such, a population with slightly raised cholesterol levels provides the relevant demographic for this explorative study. We have deliberately excluded people at high risk, who are currently on cholesterol lowering medication, which is wholly consistent with the studies outlined below by the reviewer (Shin et al, Choi et al, Hernandez-Corona et al).
2. Also, the authors based their aim on previous studies that have investigated the impact of brown seed extracts. But this studies included participants with higher baseline LDL levels: Reference 15: low dose extract: baseline LDL 3,76 ± 1,04 decreased by 10%, high dose extract LDL baseline 3,7 ± 0,78 decreased by 14,25%; Reference 16: LDL > 2,849 and LDL decreased by 11 %; Reference 17: LDL 3,1 ±0,5 and LDL decreased by 13%:
The reviewer is correct in that the three studies referred to in our manuscript had fasting baseline LDL levels above 2.0 mmol/L. Importantly, however this was not a result of a documented eligibility criteria that participants had to meet -rather this measure was reported following biochemical analyses. To emphasise, in the present study we have included the criterion that participants have a fasting LDL cholesterol level of above 2.0 mmol/L. This does not mean that the mean baseline value will be an LDL of 2.0 mmol/L, but ensures that it will be above this level (a step that two of the previous studies didn't take and still ended up with fasting baseline LDL levels above 3 mmol/L). This cut off was to ensure that we did not include any participants with fasting LDL cholesterol below this level.
3. The authors classified potential participants as subject with hypercholesterolemia, although they would be, with suggested BMI, overweight and obese. Thank you for this feedback. We have altered the title to reflect the actual nature of our participants. "A study protocol for a double blind randomised controlled trial investigating the impact of 12 weeks' supplementation with a Fucus vesiculosus extract on cholesterol levels in overweight and obese adults with elevated fasting LDL cholesterol" 4. In section Sample size calculation, the authors referred to the decrease of 0,5 mmol/L which was seen in one study. Still, in that study, the decrease of 0,5 accounted for 14% (implying that the starting values of LDL were higher than 3,5 mmol/L). On the other side, authors suggested values of LDL higher than 2 mmol/L meaning that decrease of 0,5 would account for more than 20 % (up to 25 %), which according to all studies the authors have cited (mentioned above) is not likely to occur (considering those studies included participants with higher baseline LDL values and recorded lower degree of reduction). Please refer to our earlier comment to point 1, which states that our LDL values will not be below 2.0 mmol/L as this is our cut-off for inclusion. The mean value will be higher than this. We expect the baseline LDL levels to be similar to the previous studies, as the population is also overweight and obese, and the present study has a higher BMI cut off than the previous studies. Therefore, the degree of change is expected to be similar.
5. Further on, the authors classify the extract as polyphenol-rich although the extract besides that contains fucoidan in high amounts... Thank you. We have removed the wording 'polyphenol-rich' from the title of the manuscript: "A study protocol for a double blind randomised controlled trial investigating the impact of 12 weeks' supplementation with a Fucus vesiculosus extract on cholesterol levels in overweight and obese adults with elevated fasting LDL cholesterol"
The extract used in the present study contains 600 mg of polyphenols. This dose of polyphenols is higher than that given in the three previous RCTs. Furthermore, the polyphenol content of the extract was 36.9%, according to our own analysis. This is a larger proportion of polyphenols in the extract than in two of the previous RCTs (Choi et al and Hernandez-Corona et al). We have discussed the limitation of the fucoidan content of the extract in the limitations section of the manuscript: "Another limitation of this study is the, potentially confounding, presence of fucoidan in the extract. There is evidence from animal models that fucoidan itself lowers TG, total and LDL cholesterol levels and increases HDL cholesterol. [13, 14] However, the only RCT to investigate this effect in humans used a fucoidan-rich brown seaweed extract that also contained polyphenols.
[17] Therefore, it is unclear whether the fucoidan or polyphenols were responsible for the observed reduction in LDL cholesterol following intervention.
[17] Similarly in the observed outcomes from this trial, the role of the fucoidan and polyphenols may be difficult to differentiate. Given there is in vitro and animal model evidence that both brown seaweed polyphenols and fucoidan lower cholesterol levels, [9] [10] [11] [12] [13] [14] the efficacy of the extract as a whole may be more important than determining the effect of its individual components."
